@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB00966_DB01143_nanopub.RAjEF6ab5zaCws8cySL92BCglCPyKqd7dVbEozWSID_Eg> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00966_DB01143_nanopub.RAjEF6ab5zaCws8cySL92BCglCPyKqd7dVbEozWSID_Eg#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB00966 dv:ddi-interactor-in dr:DB00966_DB01143 .
  
  d:DB01143 dv:ddi-interactor-in dr:DB00966_DB01143 .
  
  dr:DB00966_DB01143 dcterms:identifier "drugbank_resource:DB00966_DB01143";
    dcterms:title "DDI between Telmisartan and Amifostine - Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."@en;
    a dv:Drug-Drug-Interaction;
    rdfs:label "DDI between Telmisartan and Amifostine - Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine.  [drugbank_resource:DB00966_DB01143]"@en .
}

sub:provenance {
  sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MCwCFEoExpu6NF9t npx:hasPublicKey "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";
    npx:hasSignature "MCwCFEoExpu6NF9tDcwpAaA7VcEDjcx/AhRTRcu0fjweITpB9trgnzIB2bsNkA==";
    npx:signedBy instance: .
  
  this: dcterms:created "2018-03-30T11:12:40.814+02:00"^^xsd:dateTime;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFEoExpu6NF9t;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dcterms:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}